Update: 26.04.2021
Last week: 15 week 2022 (11.04.2022 - 17.04.2022)
Last full month: Mar 2022
Ситуация на рынке ЛС стабилизировалась – на 15-й неделе (относительно предыдущей) рост объёма продаж ЛП на +1,7% в упаковках и падение на -2,1% в рублях (W-o-W)
В целом картина по брендам Grindex также очень ровная – динамика продаж +/- соответствует прошлой неделе, разброс в пределах погрешности
МИЛДРОНАТ
+26,7% volume / +63,2% value (YTD)
Удержание позиций на фоне общего снижения категории – постэффект после ажиотажных недель и адаптации к новой ценовой планке
ВИПРОСАЛ
+31,1% volume / +41,1% value (YTD)
На 15 неделе Випросал показал рост выше категории – динамичнее растут большие упаковки (хроники!)
КАПСИКАМ
-3,4% volume / -2,6% value (YTD)
Пока рано говорить о результатах флайта, прошла первая неделя – продажи в небольшом плюсе относительно прошлой недели (+2,7% в упаковках)
СУЛЬФАРГИН
+6,1% volume / +12,3% value (YTD)
Небольшая, но прибавка продаж на фоне роста цен категории, в первую очередь байеровского Бепантена (средняя цена выросла на 100 руб)
АПИЛАК
+4,5% volume / +34,7% value (YTD)
Наблюдаем стабилизацию в первую очередь после значительного роста продаж большой упаковки 50 таблеток
| Time period | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 2 070 | -7.0% | 54.1% | -1.1 | 985 461 | -11.1% | 81.3% | -1.5 | -5.0% |
| MoM | 13 483 | 16.5% | 57.7% | 2 | 6 640 627 | 27.6% | 84.2% | 1.5 | 12.4% |
| YTD | 39 937 | 4.5% | 55.2% | -3.8 | 18 633 549 | 34.7% | 82.5% | 0.9 | 11.8% |
| MAT | 119 333 | -17.2% | 54.4% | -6.9 | 50 405 937 | 9.9% | 80.7% | -0.6 | -6.7% |
| KAPSIKAM | |||||||||
| WoW | 20 474 | 2.8% | 2.7% | 0 | 8 970 342 | 2.9% | 3.0% | 0.1 | 3.7% |
| MoM | 214 582 | 16.2% | 3.3% | -0.4 | 93 677 570 | 23.7% | 3.1% | -0.7 | 31.7% |
| YTD | 340 460 | -3.4% | 2.7% | -0.2 | 143 791 416 | -2.6% | 2.9% | -0.6 | 2.3% |
| MAT | 1 053 243 | -16.0% | 2.6% | -0.3 | 435 048 493 | -9.6% | 2.9% | -0.4 | -7.1% |
| MILDRONATE | |||||||||
| WoW | 93 802 | -3.3% | 23.1% | -0.1 | 64 021 250 | -1.7% | 24.6% | 0.4 | -3.1% |
| MoM | 669 749 | 31.6% | 22.6% | 0.7 | 423 078 923 | 74.3% | 23.0% | 2.4 | 27.2% |
| YTD | 1 823 556 | 26.7% | 16.8% | 2.1 | 990 931 154 | 63.2% | 17.6% | 3.7 | 10.6% |
| MAT | 5 179 587 | 14.9% | 17.1% | 2.3 | 2 317 445 437 | 28.3% | 16.0% | 2.5 | -0.9% |
| SULFARGIN | |||||||||
| WoW | 2 701 | 1.0% | 0.9% | 0 | 1 402 596 | 2.8% | 1.2% | 0.1 | -2.9% |
| MoM | 15 388 | 9.5% | 0.7% | -0.2 | 7 818 533 | 15.7% | 0.9% | -0.5 | 46.0% |
| YTD | 48 846 | 6.1% | 0.8% | 0.1 | 24 230 469 | 12.3% | 1.1% | 0.1 | -1.3% |
| MAT | 166 980 | -15.2% | 0.8% | -0.1 | 82 412 160 | -4.0% | 1.2% | 0 | -5.8% |
| VIPROSAL | |||||||||
| WoW | 23 346 | 4.0% | 2.9% | 0 | 9 987 698 | 2.9% | 3.2% | 0.1 | 3.6% |
| MoM | 152 058 | 24.2% | 4.3% | -0.2 | 65 689 053 | 35.4% | 4.1% | -0.4 | 30.8% |
| YTD | 445 119 | 31.1% | 3.3% | 0.7 | 183 421 890 | 41.1% | 3.5% | 0.6 | 2.9% |
| MAT | 1 349 017 | 1.3% | 3.1% | 0.3 | 524 700 664 | 8.8% | 3.3% | 0.2 | -6.9% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 39 937 | 4.5% | 55.2% | -3.8 | 18 633 549 | 34.7% | 82.5% | 0.9 | 11.8% |
| KAPSIKAM | 340 460 | -3.4% | 2.7% | -0.2 | 143 791 416 | -2.6% | 2.9% | -0.6 | 2.3% |
| MILDRONATE | 1 823 556 | 26.7% | 16.8% | 2.1 | 990 931 154 | 63.2% | 17.6% | 3.7 | 10.6% |
| SULFARGIN | 48 846 | 6.1% | 0.8% | 0.1 | 24 230 469 | 12.3% | 1.1% | 0.1 | -1.3% |
| VIPROSAL | 445 119 | 31.1% | 3.3% | 0.7 | 183 421 890 | 41.1% | 3.5% | 0.6 | 2.9% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 119 333 | -17.2% | 54.4% | -6.9 | 50 405 937 | 9.9% | 80.7% | -0.6 | -6.7% |
| KAPSIKAM | 1 053 243 | -16.0% | 2.6% | -0.3 | 435 048 493 | -9.6% | 2.9% | -0.4 | -7.1% |
| MILDRONATE | 5 179 587 | 14.9% | 17.1% | 2.3 | 2 317 445 437 | 28.3% | 16.0% | 2.5 | -0.9% |
| SULFARGIN | 166 980 | -15.2% | 0.8% | -0.1 | 82 412 160 | -4.0% | 1.2% | 0 | -5.8% |
| VIPROSAL | 1 349 017 | 1.3% | 3.1% | 0.3 | 524 700 664 | 8.8% | 3.3% | 0.2 | -6.9% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 2 070 | -7.0% | 54.1% | -1.1 | 985 461 | -11.1% | 81.3% | -1.5 | -5.0% |
| KAPSIKAM | 20 474 | 2.8% | 2.7% | 0 | 8 970 342 | 2.9% | 3.0% | 0.1 | 3.7% |
| MILDRONATE | 93 802 | -3.3% | 23.1% | -0.1 | 64 021 250 | -1.7% | 24.6% | 0.4 | -3.1% |
| SULFARGIN | 2 701 | 1.0% | 0.9% | 0 | 1 402 596 | 2.8% | 1.2% | 0.1 | -2.9% |
| VIPROSAL | 23 346 | 4.0% | 2.9% | 0 | 9 987 698 | 2.9% | 3.2% | 0.1 | 3.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 13 483 | 16.5% | 57.7% | 2 | 6 640 627 | 27.6% | 84.2% | 1.5 | 12.4% |
| KAPSIKAM | 214 582 | 16.2% | 3.3% | -0.4 | 93 677 570 | 23.7% | 3.1% | -0.7 | 31.7% |
| MILDRONATE | 669 749 | 31.6% | 22.6% | 0.7 | 423 078 923 | 74.3% | 23.0% | 2.4 | 27.2% |
| SULFARGIN | 15 388 | 9.5% | 0.7% | -0.2 | 7 818 533 | 15.7% | 0.9% | -0.5 | 46.0% |
| VIPROSAL | 152 058 | 24.2% | 4.3% | -0.2 | 65 689 053 | 35.4% | 4.1% | -0.4 | 30.8% |
Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs